Safety and Efficacy of Emixustat in Stargardt Disease
Public ClinicalTrials.gov record NCT03772665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
Study identification
- NCT ID
- NCT03772665
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2019 (Actual)
- Primary completion
- Jun 13, 2022 (Actual)
- Completion
- Jun 23, 2022 (Actual)
- Last update posted
- May 30, 2024
2019 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| UCSF Dept. of Ophthalmology | San Francisco | California | 94143-0730 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| The Wilmer Eye Institute Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| University of Michigan Kellogg Eye Center | Ann Arbor | Michigan | 48105 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Duke Eye Center | Durham | North Carolina | 27710 | — |
| Casey Eye Institute - OHSU | Portland | Oregon | 97239 | — |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | — |
| University of Utah John Moran Eye Center | Salt Lake City | Utah | 84132 | — |
| Medical College of Wisconsin-Eye Institute | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03772665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03772665 live on ClinicalTrials.gov.